Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002337875 | SCV002638392 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-03-30 | criteria provided, single submitter | clinical testing | The c.48_49delTCinsAT pathogenic mutation (also known as p.Y16*), located in coding exon 1 of the PTEN gene, results from an in-frame deletion of TC and insertion of AT at nucleotide positions 48 to 49. This changes the amino acid from a tyrosine to a stop codon at codon 16. An alteration leading to the same amino acid change (c.48T>A, p.Y16*) has been reported in individuals meeting relaxed International Cowden Consortium operational criteria for Cowden syndrome (Tan MH et al. Am. J. Hum. Genet. 2011 Jan; 88(1):42-56). In addition to the clinical data reported in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |